Toronto, Ontario — December 18, 2025 — Leads & Copy —
Ventripoint Diagnostics Ltd. (TSXV:VPT) will satisfy debenture interest payment obligations with the issuance of common shares, pending TSX Venture Exchange approval.
The Corporation will issue 1,145,627 common shares for an aggregate of $103,106.29 of interest on outstanding Convertible Debentures issued on May 10, 2024, June 28, 2024, September 20, 2024, January 17, 2025, February 7, 2025, and March 21, 2025. The Convertible Debentures bear interest at 10% per annum, payable every six months. The Shares will be issued at a deemed price of $0.089, subject to TSXV approval, and are subject to a hold period of four months and one day. The issuance of the Shares will not create a control person of the Corporation.
Ventripoint Diagnostics Ltd. is an industry leader in applying AI to echocardiography. Ventripoint’s VMS products use proprietary knowledge-based reconstruction technology, which provides accurate volumetric cardiac measurements equivalent to MRI. This alternative allows cardiologists greater confidence in patient management. The VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
For further information, please contact:
Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201
Source: Ventripoint Diagnostics Ltd.
